Jim W. Larrick

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Theron Pharmaceuticals, Inc. provides treatments for COPD and asthma. It is a biotechnology company, develops long acting M3 muscarinic antagonist (LAMA) products for the treatment of chronic respiratory diseases. The firm’s product TRN-157, a preclinical development therapy focuses on treating chronic obstructive pulmonary disease and severe asthma. The company was founded by M. Venkatraman, Xiaoming Zhang and Jurg Pfister in 2008 and is headquartered in Sunnyvale, CA.

Eumentis Therapeutics, Inc. manufactures novel drugs. The American company was founded by Mark A. Tepper and he has been the CEO since incorporation.

Theron Pharmaceuticals, Inc. provides treatments for COPD and asthma. It is a biotechnology company, develops long acting M3 muscarinic antagonist (LAMA) products for the treatment of chronic respiratory diseases. The firm’s product TRN-157, a preclinical development therapy focuses on treating chronic obstructive pulmonary disease and severe asthma. The company was founded by M. Venkatraman, Xiaoming Zhang and Jurg Pfister in 2008 and is headquartered in Sunnyvale, CA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Theron Pharmaceuticals, Inc. provides treatments for COPD and asthma. It is a biotechnology company, develops long acting M3 muscarinic antagonist (LAMA) products for the treatment of chronic respiratory diseases. The firm’s product TRN-157, a preclinical development therapy focuses on treating chronic obstructive pulmonary disease and severe asthma. The company was founded by M. Venkatraman, Xiaoming Zhang and Jurg Pfister in 2008 and is headquartered in Sunnyvale, CA.

Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA.